Clinical Trial

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

Study acronym: PANTHR-S
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 25, 2026 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a cohort study aimed at developing a stratified medicine approach for personalised neoadjuvant chemotherapy (NCT) in high-risk soft tissue sarcoma (STS) patients with dedifferentiated liposarcoma (DDLPS), leiomyosarcoma (LMS), synovial sarcoma (SS), vascular sarcomas, malignant peripheral nerve sheath tumour (MPNST) or other subtypes. It comprises of both retrospective and prospective tissue collection from patients advancing directly to surgery (control group) and patients receiving NCT and surgery.
Trial Details
NCT Number NCT07432932
Lead Sponsor Royal Marsden NHS Foundation Trust
Collaborators: Institute of Cancer Research, United Kingdom, University of Edinburgh, NHS Greater Glasgow and Clyde, University of Birmingham, University Hospital Birmingham, Cancer Research UK, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Hospitales Universitarios Virgen del Rocío, Andalusian Network for Design and Translation of Advanced Therapies, Instituto de Biomedicina de Sevilla, the Fundación Científica de la Asociación Española Contra el Cáncer, Associazione Italiana per la Ricerca sul Cancro, Freeman Hospital, UK, Liverpool Hospital, The Clatterbridge Cancer Centre NHS Foundation Trust
Conditions Sarcoma, Sarcoma, Leiomyo-, Adult, Sarcoma, Synovial, Adult, Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma of the Trunk and Extremities, Soft Tissue Sarcoma of the Limb, Retroperitoneal Sarcoma +4 more
Enrollment 800 participants
Start Date 2021-11-19
Primary Completion 2026-03-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-25